Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C
Evinacumab effectively lowers LDL-C in children and adolescents with HoFH. However, its ability to facilitate long-term reduction in LA frequency was not shown and remains unclear.
Authors
- Klaus Arbeiter (ORCID: https://orcid.org/0009-0002-7221-6989)
- Thomas Müller-Sacherer
- Susanne Greber‐Platzer (ORCID: https://orcid.org/0000-0002-3706-8370)
- Margot Baumgartner-Kaut
- Manuela Neyer
- Sophie Draxler-Dworzak
- Charlotte Nigmann (ORCID: https://orcid.org/0000-0002-3692-8754)
Institutions
- Comprehensive Cancer Center Vienna (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Atherosclerosis
- Published
- 2025-05-14
- DOI
- https://doi.org/10.1016/j.atherosclerosis.2025.119234
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Ultragenyx Pharmaceutical